文献速递核素与放射性配体治疗肿瘤 PET/CT

使用放射性核素实现局部体内前药活化

Localized In Vivo Prodrug Activation Using Radionuclides.
PubMed 文献 · J Nucl Med · 2025-01-03

本研究提出RAiDER策略,利用分子靶向放射性核素在病灶局部释放能量化学活化前药。体外筛选显示不同核素活化效率相差70倍,99mTc最高;小鼠模型中联合治疗延迟肿瘤生长而单药治疗未延迟(P < 0.003)。临床剂量学模拟提示可递送足够剂量活化治疗水平的前药。

要点

  • RAiDER利用靶向放射性核素局部活化前药,联合放疗与化疗。
  • 不同核素活化效率相差70倍,99mTc最高,达320 nM前药活化/Gy。
  • 小鼠中[99mTc]Tc-FAPI-34联合笼装MMAE使肿瘤活化MMAE浓度达其他组织3000倍。

核心结论

  • 概念验证研究显示RAiDER与核医学常用多种放射性核素兼容,有望安全提高放射性药物治疗癌症的疗效。
  • RAiDER有望成为治疗播散性恶性肿瘤的有效策略,并拓宽放射性药物触发多种生物学和治疗反应的能力。

研究设计与样本

  • 概念验证研究,筛查放射性核素化学活化模型辐射活化前药的能力。
  • 使用TOPAS-nBio放射生物学计算模拟套件解释实验结果。
  • 在同基因小鼠癌症模型中评估RAiDER,使用[99mTc]Tc-FAPI-34、[177Lu]Lu-FAPI-04和[177Lu]Lu-PSMA-617联合笼装MMAE或笼装依沙替康。
  • 结合小鼠生物分布与临床剂量学,估计患者放射性药物摄取与RAiDER预期活化前药浓度之间的关系。

主要发现

  • RAiDER效率在不同放射性核素间相差70倍(99mTc > 111In > 177Lu > 64Cu > 32P > 68Ga > 223Ra > 18F),99mTc每Gy暴露产生高达320 nM前药活化。
  • 计算模拟提示低能电子介导的自由基形成驱动前药活化。
  • 放射性核素活化的笼装MMAE恢复前药破坏微管的能力,细胞毒性较未活化前药提高至多2600倍。
  • 用[99mTc]Tc-FAPI-34和笼装MMAE治疗的小鼠,肿瘤中活化MMAE浓度达其他组织的至多3000倍。
  • RAiDER联合[99mTc]Tc-FAPI-34或[177Lu]Lu-FAPI-04延迟肿瘤生长,而单药治疗未延迟(P < 0.003)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radionuclides used for imaging and therapy can show high molecular specificity in the body with appropriate targeting ligands. We hypothesized that local energy delivered by molecularly targeted radionuclides could chemically activate prodrugs at disease sites while avoiding activation in off-target sites of toxicity. As proof of principle, we tested whether this strategy of radionuclide-induced drug engagement for release (RAiDER) could locally deliver combined radiation and chemotherapy to maximize tumor cytotoxicity while minimizing off-target exposure to activated chemotherapy. Methods: We screened the ability of radionuclides to chemically activate a model radiation-activated prodrug consisting of the microtubule-destabilizing monomethyl auristatin E (MMAE) caged by a radiation-responsive phenyl azide, and we interpreted experimental results using the radiobiology computational simulation suite TOPAS-nBio. RAiDER was evaluated in syngeneic mouse models of cancer using the fibroblast activation protein inhibitor (FAPI) agents [99mTc]Tc-FAPI-34 and [177Lu]Lu-FAPI-04 and the prostate-specific membrane antigen (PSMA) agent [177Lu]Lu-PSMA-617, combined with caged MMAE or caged exatecan. Biodistribution in mice, combined with clinical dosimetry, estimated the relationship between radiopharmaceutical uptake in patients and anticipated concentrations of activated prodrug using RAiDER. Results: RAiDER efficiency varied by 70-fold across radionuclides (99mTc > 111In > 177Lu > 64Cu > 32P > 68Ga > 223Ra > 18F), yielding up to 320 nM prodrug activation/Gy of exposure from 99mTc. Computational simulations implicated low-energy electron-mediated free radical formation as driving prodrug activation. Radionuclide-activated caged MMAE restored the prodrug's ability to destabilize microtubules and increased its cytotoxicity by up to 2,600-fold that of the nonactivated prodrug. Mice treated with [99mTc]Tc-FAPI-34 and caged MMAE accumulated concentrations of activated MMAE that were up to 3,000 times greater in tumors than in other tissues. RAiDER with [99mTc]Tc-FAPI-34 or [177Lu]Lu-FAPI-04 delayed tumor growth, whereas monotherapies did not (P < 0.003). Clinically guided dosimetry suggests sufficient radiation doses can be delivered to activate therapeutically meaningful levels of prodrug. Conclusion: This proof-of-concept study shows that RAiDER is compatible with multiple radionuclides commonly used in nuclear medicine and can potentially improve the efficacy of radiopharmaceutical therapies to treat cancer safely. RAiDER thus shows promise as an effective strategy to treat disseminated malignancies and broadens the capability of radiopharmaceuticals to trigger diverse biologic and therapeutic responses.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Quintana JM, Jiang F, Kang M, et al. Localized In Vivo Prodrug Activation Using Radionuclides. J Nucl Med. 2025. PMID: 39753366. doi:10.2967/jnumed.124.268559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。